Ventripoint to Exhibit the Next-Generation VMS+ System
at EuroEcho in Milan, Italy
Toronto, Ontario, November 29, 2018 – Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”, TSXV:VPT, OTCQB:VPTDF) is pleased to announce that it will be exhibiting at EuroEcho 2018, the annual congress of the European Association of Cardiovascular Imaging to showcase the next-generation VMS+ System.
With nearly 4,000 healthcare professionals from over 90 countries around the world, EuroEcho is one of the world’s largest cardiovascular imaging congresses and is a premier place to meet with world-renowned global experts in the field of cardiovascular imaging. Ventripoint will be exhibiting in booth D400 at EuroEcho held in Milan, Italy from December 5th – 7th providing hands-on demonstrations of the next-generation VMS+ System.
On December 8th at 8:30 AM, Dr. Shelby Kutty of Nebraska Children’s Hospital will be presenting a poster in section P1694 on a comparative study performed with the VMS+ System “Application of knowledge-based reconstruction to three-dimensional echocardiography and comparison with semiautomatic border detection method for evaluating ventricular function”.
The next-generation VMS+ System is designed to use Artificial Intelligence (AI) to provide a streamlined approach for volumetric measurements and ejection fractions for all 4 chambers of the heart from standard 2D echo images. Artificial Intelligence (AI) is the future of cardiac imaging and is transforming clinical outcomes. After clinician feedback, we re-designed the system to incorporate an improved user interface and smaller footprint, thereby allowing for superior integration into the clinical echography workflow and environment. The 3D guidance tracking system has also been replaced with an innovative tracking sensor technology to enable patient repositioning during the examination.
“We are excited to showcase our next-generation VMS+ System to the European market. We will have live scanning in the booth to provide the opportunity for hands-on use by the cardiology community,” notes Mehran Mehrtash, Vice-President, Worldwide Distributor Sales of Ventripoint Diagnostics.
This product is not commercially available for sale and is for investigational use only.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements:
This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management’s discussion and analysis that is available on the Corporation’s profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.